ArticleFrontiers in pharmacology2025
Network pharmacology and molecular docking analysis on molecular targets and mechanisms of scar healing ointment in the treatment of hypertrophic scars.
Article in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Causal correlation between inflammatory cytokines and hypertrophic scar based on two-sample Mendelian randomization.Journal, genetic engineering & biotechnology · 2025Article
- Editorial: Prevention and treatment of skin diseases.Frontiers in pharmacology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Hypertrophic scars (HSs) are characterized by complex mechanisms and impose substantial economic and psychological burdens on patients with wounds. Recent studies have reported that various extracts from traditional Chinese medicines can help prevent and treat HSs. Scar healing ointment (SHO), a modified traditional Chinese prescription applied externally, has demonstrated potential in the clinical treatment of HSs, though its underlying mechanisms remain unexplored. Methods: In this study, we systematically identified the active ingredients of the SHO formula and their potential targets using multiple databases (TCMSP, HERB, UniProt, GeneCards, DisGeNet, OMIM, PharmGKB, TTD) and explored the possible underlying mechanisms by which SHO treats HSs using bioinformatic analyses, including protein-protein interaction (PPI) network analysis, GO and KEGG enrichment analyses, and molecular docking. Results: Our results indicated that the primary active ingredients in the SHO formula include quercetin, beta-sitosterol, kaempferol, stigmasterol, luteolin, alloimperatorin, acacetin, and (E)-2,3-bis(7-methoxy-2-oxochromen-8-yl)prop-2-enal. Protein-protein interaction network analysis revealed that the hub target proteins of the SHO formula are AKT1, MAPK1, CCND1, TP53, GSK3B, BCL2, CDKN1A, ESR1, and MYC. GO and KEGG enrichment analyses showed that these hub target genes are involved in processes and pathways related to apoptosis and responses to oxidants. Molecular docking analysis demonstrated that the MAPK1-stigmasterol and ESR1-alloimperatorin complexes exhibited strong binding affinities (-5.31 and -6.09) and formed multiple hydrogen bonds (3 and 2, respectively). Discussion: These findings suggest that SHO may exert its effects by modulating MAPK1 and ESR1 proteins, thereby contributing to the prevention and treatment of HSs. This study offers new drugs and target candidates for the prevention and treatment of HSs and provides theoretical support for further research and application of the SHO formula. Nevertheless, additional
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.